The regulatory sweep for this desk carries one item: on 8 September 2026 the US Food and Drug Administration approved a supplement to abbreviated new drug application ANDA040671, a generic triamcinolone acetonide held by Micro Labs.
A supplement to an abbreviated application covers a manufacturing, formulation or labelling change to a product already approved. It is not a new approval, not a new indication, and carries no safety finding. No prescribing decision follows from it.
It is reported here only so that the day's regulatory activity is accounted for rather than silently absent. Inhaled corticosteroid positioning in obstructive airways disease continues to be governed by the GINA and GOLD documents, not by generic application filings — and the direction of travel in COPD in particular remains towards reserving inhaled corticosteroids for patients with exacerbations and eosinophilia rather than using them broadly.
- No action required — this is an administrative filing.
- Review inhaled corticosteroid indication at each COPD review; eosinophil count and exacerbation history are what justify it.
- Check inhaler technique before escalating any inhaled therapy, generic or branded.
- Generic substitution of inhaled products changes the device as well as the drug — confirm the patient can use the new one.
Why it matters
Separating an administrative filing from a safety action is what keeps a regulatory section worth reading.
Don't overread it
A supplement to an abbreviated new drug application is a manufacturing or labelling change, not a new indication or safety signal.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free